NASDAQ : ASBP
Aspire Biopharma Holdings, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 8.11 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 11.37M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 11.37M |
| Enterprise Value | -792,399 |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.40M |
| Shares Outstanding | 1.40M |
| Shares Change (YoY) | +1,015.92% |
| Shares Change (QoQ) | +562.40% |
| Owned by Insiders (%) | 20.11% |
| Owned by Institutions (%) | 5.41% |
| Float | 1.12M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 116.47 |
| Forward PS | n/a |
| PB Ratio | 0.89 |
| P/TBV Ratio | 0.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.99 |
| Quick Ratio | 7.22 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0.76 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -1,032.14% |
| Return on Assets (ROA) | 60.58% |
| Return on Invested Capital (ROIC) | 82.92% |
| Return on Capital Employed (ROCE) | 59.40% |
| Weighted Average Cost of Capital (WACC) | 5.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -98.28% |
| 50-Day Moving Average | 8.55 |
| 200-Day Moving Average | 17.20 |
| Relative Strength Index (RSI) | 45.20 |
| Average Volume (20 Days) | 31,398 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8,701 |
| Short Previous Month | 13,598 |
| Short % of Shares Out | 0.62% |
| Short % of Float | 0.78% |
| Short Ratio (days to cover) | 0.25 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 97,659 |
| Gross Profit | -24,452 |
| Operating Income | 7.04M |
| Pretax Income | -11.05M |
| Net Income | -11.05M |
| EBITDA | n/a |
| EBIT | 7.04M |
| Loss Per Share | -$33.33 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 12.17M |
| Total Debt | n/a |
| Net Cash | 12.17M |
| Net Cash Per Share | $8.67 |
| Equity (Book Value) | 11.76M |
| Book Value Per Share | 9.08 |
| Working Capital | 11.78M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.19M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 2.18M |
| Free Cash Flow | -7.19M |
| FCF Per Share | -$5.12 |
Margins
| Measure | Value |
|---|
| Gross Margin | -25.04% |
| Operating Margin | 7,210.15% |
| Pretax Margin | -11,314.12% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | 7,210.15% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,015.92% |
| Shareholder Yield | -1,015.92% |
| Earnings Yield | -411.01% |
| FCF Yield | -63.17% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 11, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.31 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |